Show summary Hide summary
A drug-resistant form of Shigella, the bacteria that causes painful diarrheal illness, is spreading in the United States, federal health officials warned in a recent report — a development that raises concerns because there are no FDA‑approved oral treatments for the most resistant strains. The trend has public-health implications for communities, travelers and sexual partners alike.
Rising infections, mounting resistance
Energy transition urgency spikes after Middle East crisis: Colombia urges rapid shift
Albert Sommers, former House speaker, launches bid to retake Wyoming seat
The Centers for Disease Control and Prevention’s April 9 report shows an 8.5% rise in these infections between 2011 and 2023. Health authorities estimate that Shigella is linked to roughly 450,000 infections nationwide each year, and the latest data indicate a growing share are *extensively drug‑resistant* — often referred to by the shorthand XDR.
The resistance matters because standard oral antibiotics may no longer work against XDR strains, forcing clinicians to rely on fewer, often intravenous, options. That complicates care and can increase the burden on hospitals and public-health systems.
Who is being affected now
Historically, shigellosis primarily affected young children. The CDC’s analysis of 2016–2023 cases shows a shift: many recent infections involved non-Hispanic White men. The change in affected groups alters where prevention efforts may need to focus.
Shigella spreads easily. Transmission can occur through person-to-person contact — especially when hand hygiene is poor — sexual contact, or by ingesting contaminated food or water. Because the infectious dose is low, an exposed person can become ill after swallowing only a small number of bacteria.
Symptoms and clinical concerns
Typical illness, known as shigellosis, presents with sudden-onset diarrhea that can be bloody, abdominal pain and fever. Most healthy adults recover without hospitalization, but severe or prolonged illness is more likely when treatment options are limited by resistance.
| Key fact | Latest figure / note |
|---|---|
| Reported increase (2011–2023) | 8.5% rise |
| Estimated annual U.S. infections | About 450,000 |
| Notable resistance | XDR strains resist common oral antibiotics |
| Treatment landscape | No FDA-approved oral therapy for some XDR infections |
Public-health officials have flagged the issue before: in 2023 the CDC issued an advisory highlighting XDR Shigella as an emerging challenge because of its resistance profile. The new report underscores that the problem has not abated.
Practical steps to reduce risk
The CDC recommends basic measures that lower the chance of acquiring or spreading Shigella. These are straightforward but important, especially for people in close-contact settings, travelers and those with sexual partners recently diagnosed with the infection.
- Practice thorough handwashing with soap and water after using the restroom, changing diapers or before preparing food.
- Avoid swallowing water while swimming in pools, lakes or other recreational waters.
- Follow safe food and water precautions when traveling to areas with uncertain sanitation.
- If diagnosed, refrain from sexual activity for at least two weeks after symptoms stop to limit transmission.
Officials also emphasized the need for improved detection and reporting so public-health teams can respond more quickly. Enhanced surveillance and targeted prevention — including clear guidance for clinicians on when to test and which treatments to use — are central to slowing XDR Shigella’s spread.
For most people, routine hygiene and cautious behavior while traveling or swimming will substantially reduce risk. But the rise of resistant Shigella strains is a reminder that common infections can become harder to treat, and that community-level vigilance remains essential.
